Atara Biotherapeutics (NASDAQ:ATRA) Upgraded to Strong-Buy at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) to a strong-buy rating in a research note released on Friday,Zacks.com reports.

A number of other equities research analysts have also recently commented on the stock. Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a report on Friday. They issued a “buy” rating and a $25.00 price target on the stock. Canaccord Genuity Group boosted their target price on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Atara Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $18.75.

Atara Biotherapeutics Price Performance

Shares of Atara Biotherapeutics stock opened at $11.40 on Friday. The firm has a market cap of $65.66 million, a PE ratio of -0.44 and a beta of 0.55. Atara Biotherapeutics has a 1 year low of $6.50 and a 1 year high of $39.50. The stock has a fifty day moving average price of $10.80 and a 200-day moving average price of $9.54.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter last year, the business posted ($16.50) EPS. As a group, equities analysts anticipate that Atara Biotherapeutics will post -12.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in shares of Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after buying an additional 4,043 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Atara Biotherapeutics during the 2nd quarter worth approximately $53,000. FMR LLC lifted its stake in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares in the last quarter. State Street Corp boosted its holdings in Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at $79,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.